• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Changes observed in prostate biopsy practices in an inner city hospital with a high risk patient population following the 2012 uspstf psa screening recommendations.在 2012 年 USPSTF PSA 筛查建议发布后,观察到一家市中心医院高危患者人群中前列腺活检实践的变化。
Int Braz J Urol. 2018 Jul-Aug;44(4):697-703. doi: 10.1590/S1677-5538.IBJU.2017.0348.
2
Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.2012年美国预防服务工作组关于前列腺特异性抗原筛查声明的影响:泌尿外科及初级保健实践分析
Urology. 2015 Jan;85(1):85-9. doi: 10.1016/j.urology.2014.07.072. Epub 2014 Nov 11.
3
Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.前列腺特异性抗原(PSA)筛查试验和修订的 PSA 筛查指南对前列腺活检率和活检后并发症的影响。
Eur Urol. 2017 Jan;71(1):55-65. doi: 10.1016/j.eururo.2016.03.015. Epub 2016 Mar 16.
4
Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.美国预防服务工作组建议反对基于前列腺特异性抗原的筛查时代的前列腺穿刺活检结果
J Urol. 2016 Jan;195(1):66-73. doi: 10.1016/j.juro.2015.07.099. Epub 2015 Aug 6.
5
US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.美国预防服务工作组前列腺特异性抗原筛查指南导致更高的格里森评分诊断。
Investig Clin Urol. 2017 Nov;58(6):423-428. doi: 10.4111/icu.2017.58.6.423. Epub 2017 Nov 2.
6
Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates.美国预防服务工作组关于反对前列腺特异性抗原筛查的建议对前列腺活检及癌症检出率的影响。
J Urol. 2015 May;193(5):1519-24. doi: 10.1016/j.juro.2014.11.096. Epub 2014 Dec 3.
7
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.前列腺癌筛查:美国预防服务工作组推荐声明。
JAMA. 2018 May 8;319(18):1901-1913. doi: 10.1001/jama.2018.3710.
8
Prostate cancer screening practices in a large, integrated health system: 2007-2014.大型综合医疗系统中的前列腺癌筛查实践:2007 - 2014年
BJU Int. 2017 Aug;120(2):257-264. doi: 10.1111/bju.13793. Epub 2017 Feb 26.
9
Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.在预防工作组建议反对前列腺特异性抗原筛查后,前列腺活检结果的变化。
BMC Urol. 2018 Aug 20;18(1):69. doi: 10.1186/s12894-018-0384-x.
10
Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.美国预防服务工作组最终建议前后基层医疗医生的前列腺特异性抗原筛查做法。
Urol Oncol. 2014 Jan;32(1):41.e23-30. doi: 10.1016/j.urolonc.2013.04.013. Epub 2013 Aug 2.

引用本文的文献

1
Impact on prostate cancer clinical presentation after non-screening policies at a tertiary-care medical center- a retrospective study.非筛查政策对三级医疗中心前列腺癌临床表现的影响-一项回顾性研究。
BMC Urol. 2021 Feb 8;21(1):20. doi: 10.1186/s12894-021-00784-w.

本文引用的文献

1
The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment.美国预防服务工作组2017年关于前列腺癌筛查的建议声明草案:邀请审查与评论。
JAMA. 2017 May 16;317(19):1949-1950. doi: 10.1001/jama.2017.4413.
2
NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.美国国立综合癌症网络(NCCN)指南解读:前列腺癌早期检测,2016年第2版
J Natl Compr Canc Netw. 2016 May;14(5):509-19. doi: 10.6004/jnccn.2016.0060.
3
Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.美国预防服务工作组建议反对基于前列腺特异性抗原的筛查时代的前列腺穿刺活检结果
J Urol. 2016 Jan;195(1):66-73. doi: 10.1016/j.juro.2015.07.099. Epub 2015 Aug 6.
4
Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.2012年美国预防服务工作组关于前列腺特异性抗原筛查声明的影响:泌尿外科及初级保健实践分析
Urology. 2015 Jan;85(1):85-9. doi: 10.1016/j.urology.2014.07.072. Epub 2014 Nov 11.
5
Reclassification rates are higher among African American men than Caucasians on active surveillance.在主动监测中,非裔美国男性的重新分类率高于白种人。
Urology. 2015 Jan;85(1):155-60. doi: 10.1016/j.urology.2014.08.014. Epub 2014 Oct 14.
6
Predictors of Gleason score upgrading in a large African-American population.在一个大型非裔美国人人群中,预测格里森评分升级的因素。
Int Urol Nephrol. 2013 Oct;45(5):1257-62. doi: 10.1007/s11255-013-0495-y. Epub 2013 Jul 18.
7
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.前列腺癌筛查:美国预防服务工作组推荐声明。
Ann Intern Med. 2012 Jul 17;157(2):120-34. doi: 10.7326/0003-4819-157-2-201207170-00459.
8
Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance.与主动监测患者前列腺癌进展相关的临床和人口统计学特征。
J Urol. 2012 May;187(5):1594-9. doi: 10.1016/j.juro.2011.12.082. Epub 2012 Mar 14.
9
Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity.有证据表明,黑人男性前列腺癌的生长速度比白人男性更快,/或更早向具有临床意义的前列腺癌转化,/且这种差异影响了癌症的进展和死亡率的种族差异。
J Urol. 2010 May;183(5):1792-6. doi: 10.1016/j.juro.2010.01.015. Epub 2010 Mar 17.
10
Screening and prostate-cancer mortality in a randomized European study.一项欧洲随机研究中的筛查与前列腺癌死亡率
N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.

在 2012 年 USPSTF PSA 筛查建议发布后,观察到一家市中心医院高危患者人群中前列腺活检实践的变化。

Changes observed in prostate biopsy practices in an inner city hospital with a high risk patient population following the 2012 uspstf psa screening recommendations.

机构信息

Department of Urology, University Hospital of Brooklyn, State University of New York Downstate College of Medicine, Brooklyn, NY, USA.

Department of Public Health Sciences and Division of Epidemiology, University of Rochester Medical Center, Rochester, NY, USA.

出版信息

Int Braz J Urol. 2018 Jul-Aug;44(4):697-703. doi: 10.1590/S1677-5538.IBJU.2017.0348.

DOI:10.1590/S1677-5538.IBJU.2017.0348
PMID:29617073
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6092647/
Abstract

INTRODUCTION

We compared characteristics of patients undergoing prostate biopsy in a high-risk inner city population before and after the 2012 USPSTF recommendation against PSA based prostate cancer screening to determine its effect on prostate biopsy practices.

MATERIALS AND METHODS

This was a retrospective study including patients who received biopsies after an abnormal PSA measurement from October 2008-December 2015. Patients with previously diagnosed prostate cancer were excluded. Chi-square tests of independence, two sample t-tests, Mann-Whitney U tests, and Fisher's exact tests were performed.

RESULTS

There were 202 and 208 patients in the pre-USPSTF and post-USPSTF recommendation cohorts, respectively. The post-USPSTF cohort had higher median PSA (7.8 versus 7.1ng/mL, p=0.05), greater proportion of patients who were black (96.6% versus 90.5%, p=0.01), and greater percentage of biopsy cores positive for disease (58% versus 29.5%, p<0.001). Multivariable analysis supported that the increase in PSA was independent of the increase in the proportion of patients who were black. The proportion of patients who were classified as D'Amico intermediate and high-risk disease increased in the post-USPSTF cohort and approached statistical significance (70.1% versus 58.8%, p=0.12).

CONCLUSIONS

Our study suggests that the USPSTF recommendations may have led to na increase in pre-biopsy PSA as well as greater volume of disease. Also, a greater proportion of patients were being classified with intermediate or high risk disease. While the clinical significance of these findings is unknown, what the data suggests is somewhat troubling. Future research should further examine these changes in a larger cohort as well as resultant long-term outcomes.

摘要

介绍

我们比较了 2012 年 USPSTF 建议反对基于 PSA 的前列腺癌筛查后,在高风险市中心人群中接受前列腺活检的患者特征,以确定其对前列腺活检实践的影响。

材料和方法

这是一项回顾性研究,包括 2008 年 10 月至 2015 年 12 月期间因 PSA 异常而接受活检的患者。排除了先前诊断为前列腺癌的患者。进行了独立性卡方检验、两样本 t 检验、Mann-Whitney U 检验和 Fisher 精确检验。

结果

在 USPSTF 建议之前和之后的队列中,分别有 202 名和 208 名患者。后 USPSTF 队列的中位 PSA 更高(7.8 与 7.1ng/mL,p=0.05),黑人患者比例更高(96.6%与 90.5%,p=0.01),活检阳性核心的比例更大(58%与 29.5%,p<0.001)。多变量分析支持 PSA 的增加独立于黑人患者比例的增加。在后 USPSTF 队列中,D'Amico 中高危疾病患者的比例增加,并接近统计学意义(70.1%与 58.8%,p=0.12)。

结论

我们的研究表明,USPSTF 的建议可能导致活检前 PSA 增加以及疾病负担增加。此外,更多的患者被归类为中高危疾病。虽然这些发现的临床意义尚不清楚,但数据表明有些令人不安。未来的研究应该在更大的队列中进一步检查这些变化以及由此产生的长期结果。